{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-086406","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-07-23T23:54:03+00:00","discovered_at":"2026-07-24T10:05:00.240748+00:00","generated_at":"2026-07-24T10:05:45.099628+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Outlook Therapeutics grants stock options and FDA-contingent cash bonuses to CEO and CFO","bullets":["CEO Robert C. Jahr granted 100,000 stock options at $1.4304/share, vesting July 21, 2027.","CFO Lawrence A. Kenyon granted 210,078 stock options at same price and vesting schedule.","Cash bonuses of $420,000 (Jahr) and $200,000 (Kenyon) contingent on FDA approval of ONS-5010 by July 31, 2026.","Bonuses awarded for 2025 service contributions and BLA advancement; no 2025 annual bonuses paid.","Options and bonuses approved by Compensation Committee on July 21, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-086406","json":"https://secwatch.observer/filing/0001104659-26-086406.json","markdown":"https://secwatch.observer/filing/0001104659-26-086406.md","text":"https://secwatch.observer/filing/0001104659-26-086406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926086406/0001104659-26-086406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926086406/tm2621232d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-24T10:05:45.099628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}